Clumeck N, DeJesus E, et al. Maraviroc for previously treated individuals with R5 HIV-1 infection. N Engl J Med 359: 14291441. five. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AIM, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359: 14421455. doi:10.1056/NEJMoa0803154. six. Knapp DJHF, McGovern RA, Dong W, Poon AFY, Swenson LC, et al. Components influencing the sensitivity and specificity of traditional sequencing in human immunodeficiency virus form 1 tropism testing. J Clin Microbiol 51: 444 451. doi:10.1128/JCM.00739-12. 7. Sing T, 15481974 Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. Predicting HIV coreceptor usage around the basis of genetic and clinical covariates. Antivir Ther 12: 10971106. eight. Soriano V, Perno C-F, Kaiser R, Calvez V, Gatell JM, et al. When and tips on how to use maraviroc in HIV-infected sufferers. AIDS 23: 23772385. doi:10.1097/QAD.0b013e328332d32d. 9. Wasmuth J-C, Rockstroh JK, Hardy WD Drug safety evaluation of maraviroc for the remedy of HIV infection. Specialist Opin Drug Saf 11: 161 174. doi:ten.1517/14740338.2012.640670. ten. Briz V, Poveda E, del Mar Gonzalez M, Martin-Carbonero L, Gonzalez Gonzalez R, et al. Nobiletin Impact of antiretroviral therapy on viral tropism in HIV-infected Tubastatin A patients followed longitudinally for more than five years. J Antimicrob Chemother 61: 405410. doi:10.1093/jac/dkm469. 11. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, et al. R5 to X4 switch in the predominant HIV-1 population in cellular reservoirs in the course of powerful extremely active antiretroviral therapy. J Acquir Immune Defic Syndr 38: 382392. 12. Seclen E, Del Mar Gonzalez M, De Mendoza C, Soriano V, Poveda E 1315463 Dynamics of HIV tropism below suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 65: 14931496. doi:ten.1093/jac/dkq156. 13. Soulie C, Lambert-Niclot S, Wirden M, Simon A, Valantin M-A, et al. Low frequency of HIV-1 tropism evolution in sufferers successfully treated for a minimum of two years. AIDS 25: 537539. doi:10.1097/QAD.0b013e32834345d3. 14. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, et al. Enhanced detection of CXCR4-using HIV by V3 genotyping: application of populationbased and ��deep��sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 54: 506510. 15. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, et al. Concordance in between HIV-1 genotypic coreceptor tropism predictions primarily based on plasma RNA and proviral DNA. HIV Med 12: 544552. 16. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, et al. CoReceptor Switch In the course of HAART Is Independent of Virological Results. J Med Virol 81: 20362044. doi:ten.1002/jmv. 17. Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, et al. Evolution of proviral DNA HIV-1 tropism below selective pressure of maraviroc-based therapy. J Antimicrob Chemother 67: 14791485. doi:ten.1093/jac/dks055. 18. Paar C, Geit M, Stekel H, Berg J Genotypic prediction of human immunodeficiency virus sort 1 tropism by use of plasma and peripheral blood mononuclear cells within the routine clinical laboratory. J Clin Microbiol 49: 2697 2699. doi:ten.1128/JCM.00336-11. 19. Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol 49: 14411445. 20. Prosperi MCF, Bracciale L, Fabbiani M, Di Giambenedetto.Clumeck N, DeJesus E, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359: 14291441. five. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AIM, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359: 14421455. doi:ten.1056/NEJMoa0803154. six. Knapp DJHF, McGovern RA, Dong W, Poon AFY, Swenson LC, et al. Components influencing the sensitivity and specificity of traditional sequencing in human immunodeficiency virus sort 1 tropism testing. J Clin Microbiol 51: 444 451. doi:10.1128/JCM.00739-12. 7. Sing T, 15481974 Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. Predicting HIV coreceptor usage around the basis of genetic and clinical covariates. Antivir Ther 12: 10971106. 8. Soriano V, Perno C-F, Kaiser R, Calvez V, Gatell JM, et al. When and tips on how to use maraviroc in HIV-infected individuals. AIDS 23: 23772385. doi:ten.1097/QAD.0b013e328332d32d. 9. Wasmuth J-C, Rockstroh JK, Hardy WD Drug security evaluation of maraviroc for the remedy of HIV infection. Specialist Opin Drug Saf 11: 161 174. doi:10.1517/14740338.2012.640670. ten. Briz V, Poveda E, del Mar Gonzalez M, Martin-Carbonero L, Gonzalez Gonzalez R, et al. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for more than five years. J Antimicrob Chemother 61: 405410. doi:10.1093/jac/dkm469. 11. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, et al. R5 to X4 switch of your predominant HIV-1 population in cellular reservoirs for the duration of helpful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38: 382392. 12. Seclen E, Del Mar Gonzalez M, De Mendoza C, Soriano V, Poveda E 1315463 Dynamics of HIV tropism beneath suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 65: 14931496. doi:ten.1093/jac/dkq156. 13. Soulie C, Lambert-Niclot S, Wirden M, Simon A, Valantin M-A, et al. Low frequency of HIV-1 tropism evolution in individuals successfully treated for no less than 2 years. AIDS 25: 537539. doi:ten.1097/QAD.0b013e32834345d3. 14. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, et al. Enhanced detection of CXCR4-using HIV by V3 genotyping: application of populationbased and ��deep��sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 54: 506510. 15. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, et al. Concordance among HIV-1 genotypic coreceptor tropism predictions primarily based on plasma RNA and proviral DNA. HIV Med 12: 544552. 16. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, et al. CoReceptor Switch In the course of HAART Is Independent of Virological Accomplishment. J Med Virol 81: 20362044. doi:10.1002/jmv. 17. Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, et al. Evolution of proviral DNA HIV-1 tropism beneath selective stress of maraviroc-based therapy. J Antimicrob Chemother 67: 14791485. doi:ten.1093/jac/dks055. 18. Paar C, Geit M, Stekel H, Berg J Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Microbiol 49: 2697 2699. doi:10.1128/JCM.00336-11. 19. Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol 49: 14411445. 20. Prosperi MCF, Bracciale L, Fabbiani M, Di Giambenedetto.

Clumeck N, DeJesus E, et al. Maraviroc for previously treated individuals

About author

Leave a reply

You must be logged in to post a comment.